Advanced heart failure

Article written and reviewed by Dr Luca Moretti

Advanced heart failure is a persistent clinical phase in which severe symptoms, episodes of congestion or low cardiac output, and substantial cardiac dysfunction continue despite appropriate maximal therapy, making assessment for transplantation, mechanical support, intermittent therapies, or specialist palliative care necessary. It is not synonymous with a very low ejection fraction or NYHA class IV alone. The Heart Failure Association definition requires a combination of severe heart disease, substantial symptoms, episodes of worsening, and marked objective limitation despite attempts at optimization. Forms with preserved ejection fraction, right heart dysfunction, and congenital, restrictive, or valvular heart disease can reach the same stage; timely recognition is crucial because there is a window of eligibility. Kidney function, liver function, pulmonary vascular resistance, infections, malignancies, frailty, and social support may deteriorate until options that would have been possible months earlier become unfeasible.

Warning signs are summarized by tools such as “I NEED HELP”: inotropes, persistently impaired NYHA class, organ damage, a very reduced ejection fraction, ICD shocks, hospitalizations, refractory edema, low blood pressure, and intolerance of prognosis-modifying drugs. Even one may justify discussion with an advanced heart failure center; there is no need to wait until all are present. “Advanced” does not automatically mean terminal. Some patients improve after revascularization, ablation, valve correction, CRT, or completion of therapy; others achieve long survival with LVAD or transplantation; assessment also serves to discover untapped reversibility. When replacement therapies are not indicated or desired, the same diagnosis enables an active palliative plan for dyspnea, edema, pain, anxiety, devices, and place of care, avoiding hospitalizations and procedures inconsistent with the goals.

Etiology, pathogenesis, and pathophysiology

Ischemic heart disease and dilated cardiomyopathy are predominant causes, but etiology varies with age and population. Myocarditis, sarcoidosis, amyloidosis, genetic heart diseases, valvular disease, congenital heart disease, and toxicity may progress despite treatment; identifying the substrate remains important even in the advanced phase because it can change transplantation, arrhythmia management, and family screening. Progression is not linear. Episodes of worsening heart failure cause myocardial and multiorgan damage, followed by incomplete recovery; other patients decline slowly with low cardiac output, frailty, and treatment intolerance without dramatic hospitalizations. An apparently irreversible cause may contain treatable components: ischemia, tachycardia, dyssynchrony, functional regurgitation, iron deficiency, or sleep apnea; advanced assessment checks that these opportunities have not been missed.

Reduced cardiac output and blood pressure activate the sympathetic nervous system, the renin-angiotensin-aldosterone system, and vasopressin. Vasoconstriction and retention temporarily sustain perfusion but increase afterload, congestion, arrhythmias, and oxygen consumption; in the advanced stage, neurohormonal reserve becomes maladaptive and limits tolerance of the drugs that antagonize it. Elevated venous pressure reduces the perfusion gradient of the kidneys and liver. Kidney injury, hyponatremia, cholestasis, and coagulopathy are not merely comorbidities, but indicators of hemodynamic severity and determinants of procedures. Intestinal edema alters absorption and barrier function, while inflammation and anorexia promote cachexia; the patient may lose tissue while gaining weight from water.

The right ventricle is a key prognostic determinant. Pulmonary hypertension, tricuspid regurgitation, and ventricular interdependence reduce pulmonary blood flow and left ventricular preload; substantial right heart dysfunction increases LVAD risk and may require temporary support or rule out an isolated strategy. Chronically elevated pulmonary vascular resistance exposes the donor heart to right heart failure; catheterization and reversibility testing distinguish a reactive component from fixed remodeling and guide heart transplantation, heart-lung transplantation, or other strategies. In restrictive or congenital cardiomyopathies, small cavities and complex anatomy may limit LVAD use despite severe heart failure; the center’s experience is part of feasibility.

Advanced remodeling produces dilation, wall stress, mitral and tricuspid regurgitation, subendocardial ischemia, and fibrosis. Ventricular arrhythmias and fibrillation worsen cardiac output; ICD shocks are markers of both electrical instability and progression. Intolerance of ARNI, ACEi, beta-blockers, or MRA because of hypotension, kidney dysfunction, or hyperkalemia may be a sign of low reserve, not a reason to label therapy as “complete.” Corrective measures are sought, but progressive loss of drug classes is a referral signal; an SGLT2 inhibitor has modest blood pressure effects and often remains usable, but shock, fasting, ketoacidosis, or procedures require appropriate temporary withholding.

Exercise capacity depends on cardiac output, pulmonary pressure, chronotropic function, and muscle. Peak VO2 falls, the ventilatory slope increases, and oscillatory ventilation may appear; prognostic values must be interpreted in light of effort, age, sex, obesity, and beta-blocker therapy. Frailty results from inflammation, inactivity, hospitalizations, malnutrition, and cognitive impairment. Some components are reversible with rehabilitation and nutrition, while others reflect irreversible vulnerability; the distinction influences transplantation and LVAD. Low blood pressure, reduced reserve, and peripheral vasoconstriction cause exercise intolerance before overt hypotension appears; patient-reported functional decline is therefore an early sign.

In cardiogenic shock, a critical loss of cardiac output produces hypoperfusion and multiorgan damage; the phenotype may be left-sided, right-sided, or biventricular and coexist with inflammatory vasodilation; lactate and blood pressure alone do not describe the physiology. Inotropes temporarily increase cardiac output but expose the patient to arrhythmias and mortality and can create inotrope dependence; inability to wean defines an advanced profile requiring a decision on bridging, destination therapy, or palliation. Temporary mechanical support interrupts hypoperfusion as a bridge to recovery or decision, but delay, incorrect selection, and vascular complications may turn support into additional harm.

Clinical manifestations

Dyspnea with minimal activity or at rest, orthopnea, edema, ascites, and fatigability are common. Symptoms may fluctuate with diuretics, but a growing requirement or an increasingly short window of euvolemia signals refractory congestion; low cardiac output causes cold extremities, a narrow pulse pressure, confusion, oliguria, anorexia, and drowsiness. Hypotension may be absent because of vasoconstriction, so renal and functional deterioration must not be ignored as long as systolic pressure remains above a threshold. Angina, palpitations, syncope, and ICD shocks require investigation for ischemia and arrhythmias. Repeated appropriate device therapies indicate high risk even if congestion is modest.

Repeated hospitalizations, urgent presentations, and outpatient infusions are manifestations of the trajectory. Every episode of worsening counts, even without hospitalization, because it signals failure of stability and predicts events; the vulnerable interval after discharge carries high risk. Residual congestion, missing therapy, and delayed follow-up promote return, while early review allows adjustments and possible referral for advanced care; a patient who is not hospitalized because they receive home care may have equally advanced disease. The definition must not depend on healthcare organization.

Physical signs include jugular venous distention, hepatojugular reflux, a third heart sound, functional murmurs, crackles, effusions, edema, and ascites; the absence of findings after diuresis does not eliminate the diagnosis if the limitation and history remain severe. Cachexia, temporal wasting, reduced grip strength, and slowness indicate biological frailty. An elevated BMI does not exclude muscle loss and may conceal sarcopenic obesity. Orthostatic symptoms, falls, and delirium signal vulnerability to medications and hospitalization. Cognition and the ability to manage devices must be assessed with caregivers.

INTERMACS profiles describe severity in candidates for support: critical shock, progressive decline, inotrope-dependent stability, symptoms at rest, or marked limitation. They are a clinical language and not a score that automatically determines the device; the ambulatory advanced profile may appear stable but involve living with minimal activity, high doses, and low blood pressure. Intervention before shock offers better outcomes and more options. In congenital heart disease, amyloidosis, or HFpEF, classic signs of dilation may be absent. Ascites, arrhythmias, liver disease, and low peak VO2 become more important.

The psychological burden includes fear of death, shocks, dependence, costs, and the burden on the caregiver. Depression and anxiety influence decisions but must not be confused with informed refusal; specialist support facilitates an authentic choice; refractory dyspnea may persist despite euvolemia because of pulmonary hypertension, weakness, and anxiety. Low-dose morphine may be considered within a selected palliative pathway, with attention to kidney function and sedation. Pain, insomnia, pruritus, nausea, and constipation are important and often neglected symptoms; advanced care is not limited to blood pressure and diuretics.

Investigations and diagnosis

Assessment confirms diagnosis, severity, reversibility, and eligibility. ECG and monitoring evaluate ischemia, QRS, and arrhythmias; echocardiography defines both ventricles, valves, pressures, and thrombi; comparison over time is more useful than a snapshot. BNP or NT-proBNP, troponin, complete blood count, iron status, kidney function, electrolytes, liver function, coagulation, albumin, and urine testing define the multiorgan burden. TSH, inflammatory markers, and etiological tests are added according to suspicion; an ejection fraction below 30% is a possible but not mandatory criterion. Cardiac output, right heart function, and pressures may reflect terminal disease with a less impaired ejection fraction.

Cardiopulmonary exercise testing measures peak VO2, percent predicted, VE/VCO2, blood pressure, and rhythm. Thresholds around 12 mL/kg/min with beta-blockade or 14 without are historical references for transplantation, not absolute decision rules; percent predicted is useful in young people, women, and obesity. Maximal effort is verified using the respiratory exchange ratio and clinical behavior; a submaximal test cannot be interpreted as evidence of good reserve. The six-minute walk test is simpler and tracks the trajectory, but depends on motivation and the musculoskeletal system. Both tests are integrated with prognosis and preferences.

Right heart catheterization measures atrial, pulmonary, and wedge pressures, cardiac output, and vascular resistance. It is essential for transplantation, shock, and uncertainty about physiology; volume status, oxygen, and drugs must be recorded because they change the values. A low cardiac index, high atrial and wedge pressures, and elevated pulmonary vascular resistance identify risk, but the decision requires reversibility assessment and trends. Testing with vasodilators or decongestion is performed in an experienced setting. Coronary angiography, magnetic resonance imaging, PET, or biopsy are used when a treatable cause is still plausible; the advanced workup must not become an automatic repetition of tests that are already conclusive.

Scores such as the Seattle Heart Failure Model and Heart Failure Survival Score estimate risk, but are complementary. Contemporary therapies, devices, and specific populations may alter their calibration; no value replaces assessment of the clinical trajectory; mortality risk without advanced therapy is compared with procedural risk and expected benefit. Chronological age is insufficient: frailty, kidney function, liver function, lung function, and malignancies carry different weights for transplantation and LVAD; nutritional, dental, infectious, vascular, and oncological assessment identifies modifiable risks. Vaccinations and screening should be completed before immunosuppressive therapy whenever possible.

For transplantation, blood group, HLA sensitization, anatomy, pulmonary vascular resistance, and extracardiac conditions are defined; psychosocial assessment includes understanding, adherence, addictions, support, and self-management ability, using fair and nonpunitive criteria. For LVAD, right heart function, valves, the aorta, coagulation, infections, thoracic anatomy, and the ability to manage the driveline and anticoagulation are assessed. Previous stroke or vascular disease does not automatically preclude treatment, but modifies risk. Potentially reversible frailty can be addressed with prehabilitation; severe and progressive vulnerability may make the procedure disproportionate.

Palliative care requires parallel assessment of symptoms, prognosis, values, and caregiver burden; a discussion about resuscitation and the ICD does not equate to abandoning diuretics, palliative inotropes, or tolerated disease-modifying therapies. Shared decision-making is repeated when status and options change. Advance directives identify the surrogate decision-maker and preferences regarding support, hospitalization, and death at home. When uncertainty is high, a time-limited therapeutic trial with explicit goals may clarify benefit. Criteria for success and discontinuation should be agreed upon beforehand.

Treatment and prognosis

Before defining refractoriness, effective therapies are optimized according to phenotype. In HFrEF, the four pillars are maintained at tolerated doses; hypotension prompts correction of volume status and review of nitrates and nonessential drugs before abandoning entire classes. Loop diuretics, sequential blockade, and sometimes infusions control congestion. Early urinary sodium, urine output, weight, jugular veins, and organ function guide the response; ultrafiltration is reserved for selected cases and does not replace a competent pharmacological strategy. Iron deficiency, arrhythmias, ischemia, valvular disease, sleep apnea, and infections are treated. CRT and ICD follow criteria, but a procedure must not delay referral if the probability of recovery is low.

Intravenous inotropes are indicated in shock or as a bridge in dependent patients. Dobutamine and milrinone differ in receptors, renal considerations, and blood pressure effects; both increase arrhythmic risk; chronic use may serve as a bridge to transplantation/LVAD or as palliation, with an explicit goal. Vasopressors maintain perfusion in shock, while temporary support is selected according to phenotype; a response-based strategy of early escalation avoids increasing catecholamine doses without a solution. Shock teams and rapid transfer improve coordination among revascularization, device support, and decision-making, but appropriateness depends on reversibility and neurological and multiorgan status.

Transplantation replaces the heart and offers high survival and quality of life to selected candidates. Allocation balances urgency, benefit, waiting time, and availability; donation after circulatory death has expanded the pool, with noninferior early outcomes in contemporary studies. Contraindications may be absolute or relative and change with treatment and guidelines. Active malignancy, uncontrolled infection, irreversible extracardiac damage, or uncorrectable pulmonary vascular resistance may make the risk excessive. After transplantation, rejection, infections, cardiac allograft vasculopathy, malignancies, and immunosuppressive toxicity require lifelong follow-up. It is not a cure that requires no treatment.

Continuous-flow LVADs may serve as a bridge to transplantation or as destination therapy. Magnetically levitated devices have reduced thrombosis and reoperations compared with previous generations, but bleeding, stroke, infection, and right heart failure remain important complications. Selection and timing determine the outcome: implantation before irreversible shock and severe organ damage is preferable; support at home requires daily management, power, dressings, anticoagulation, and a caregiver or adequate network. Blood pressure, the aorta, valves, and right heart function are monitored; device flow does not replace physiology, and excessive speed may collapse the ventricle or shift the septum.

Secondary mitral regurgitation may benefit from transcatheter repair in selected anatomy and proportions after optimal therapy. Aortic stenosis, tricuspid stenosis, and coronary artery disease are managed through the Heart Team; procedures must offer a realistic probability of changing symptoms or eligibility; ablation of atrial fibrillation may improve function in arrhythmia-induced cardiomyopathy, but advanced atrial disease and instability reduce success. Ventricular ablation controls shocks but does not correct pump function. In congenital heart disease, Fontan circulation, or restrictive heart disease, surgical strategies, mechanical support, and transplantation are highly specialized; standard criteria are not applied without anatomical adaptation.

Palliative care controls dyspnea with decongestion, ventilation when aligned with goals, selected opioids, and psychological support; it addresses pain, insomnia, depression, and caregivers. Hospice is appropriate when prognosis and goals indicate it, but palliation may begin years earlier; deactivation of the ICD’s antitachycardia therapies avoids painful shocks in the terminal phase and does not turn off pacing. The decision is discussed and documented, with the possibility of revision; prognosis without replacement therapy is heterogeneous. Hospitalizations, inotropes, hyponatremia, right heart and organ damage, low VO2, and frailty indicate risk; appropriate communication includes uncertainty and alternatives.

Complications

Cardiogenic shock and multiorgan damage are the most immediate complications. The kidneys, liver, intestine, and brain deteriorate with low perfusion and high venous pressure; beyond a threshold, reversibility decreases even if cardiac output is restored. Inotropes cause tachyarrhythmias and ischemia, while vasopressors increase afterload and peripheral ischemia. Monitoring and an exit plan are essential. Temporary support may cause bleeding, hemolysis, limb ischemia, stroke, and infection; absence of recovery or eligibility requires reassessment of the proportionality of care.

Atrial and ventricular arrhythmias cause instability, ICD shocks, and sudden death; congestion, ischemia, and potassium or magnesium imbalances increase vulnerability; amiodarone and ablation have selected roles but also adverse effects. Electrical storm requires sedation, correction of triggers, drugs, device programming, and ablation, together with pump support. Repeated shocks worsen stress and prognosis. Bradycardia, conduction block, and device malfunction may reduce cardiac output. Remote and timely checks prevent some decompensations.

Cardiorenal syndrome causes diuretic resistance and electrolyte disturbances. Dialysis may be necessary for renal or volume indications, but does not correct low cardiac output; modality and rate must respect stability. Congestive hepatopathy, fibrosis, and hypoxic hepatitis increase bleeding and operative risk. Imaging, laboratory testing, and sometimes biopsy distinguish reversibility and the need for combined transplantation. Hyponatremia indicates vasopressin activation and severity; overly rapid correction is dangerous, and the main treatment remains directed at the underlying physiology.

In LVAD recipients, gastrointestinal bleeding, acquired von Willebrand disease, stroke, thrombosis, driveline infection, and aortic regurgitation require surveillance; anticoagulation is adapted to the device and the evidence, not arbitrarily discontinued. Post-LVAD right heart failure may require inotropes, inhaled vasodilators, or right-sided support and worsens outcomes. Decongestion and preimplantation selection are preventive but do not eliminate risk. Technical failures and power interruptions are emergencies. Patients, caregivers, and services must know the contacts and procedures.

After transplantation, cellular or antibody-mediated rejection may be asymptomatic or cause dysfunction and shock. Opportunistic infections and malignancies increase with immunosuppression; cardiac allograft vasculopathy may progress without angina because of denervation. Nephrotoxicity, diabetes, hypertension, and post-transplant frailty require multidisciplinary prevention. Adherence and drug interactions are decisive; limited organ availability entails waiting-list mortality and a need for bridging. Deterioration must be communicated to the center immediately.

Cachexia, sarcopenia, depression, and cognitive deterioration reduce survival and independence; nutrition must balance sodium, protein, kidney function, and symptoms; supplements without congestion management are insufficient. Repeated hospitalizations increase infections, delirium, and functional loss. Mobilization and prehabilitation protect eligibility while this is still possible; the terminal phase may include refractory dyspnea and edema, hypotension, and drowsiness. An advance plan for diuretics, ICD, emergencies, and family support reduces suffering and unwanted interventions.